Latest court orders, judgments, and legal developments from Indian courts — AI-curated and summarized.
FeaturedThe Indian Patent Office’s Draft Guidelines for Examination of Pharmaceutical Patent Applications (2026) face strong criticism for misquoting statutory provisions and misinterpreting legal standards. Stakeholders call for substantial revision before finalization.
FeaturedThe Delhi High Court, in Fresenius Kabi v. Controller, set aside the rejection of a patent application for Sugammadex, citing procedural flaws under Section 14 of the Patents Act. The Court criticized the use of hindsight and mosaicking in prior art analysis.
FeaturedThe Delhi High Court set aside the Controller’s refusal of Fresenius Kabi’s Sugammadex patent, citing procedural flaws under Section 14 of the Patents Act. The order underscores strict compliance with hearing requirements and warns against hindsight bias in inventive step analysis.
The IPO’s Draft Guidelines for Examination of Pharmaceutical Patent Applications, 2026, have drawn strong criticism for misquoting statutory provisions and introducing legally unsound interpretations. Stakeholders urge comprehensive revision before finalization.
The CGPDTM has issued new draft guidelines aimed at improving the examination process of pharmaceutical and biotechnology patent applications.